Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1848-1851

  Kressner, U ^a,d   Glimelius, B ^a   Bergstrom R ^b   Pahlman L ^a   Larsson, A ^a   Lindmark, G ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d Buskerud Central Hospital   (Norway)

Author keywords

Colorectal cancer; Immunohistochemistry; Serum p53 antibody; Survival; Tumour differentiation; Tumour stage

Indexed keywords

ANTIBODY; PROTEIN P53;

AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

EID: 0031802005     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.307     Document Type: Article

References (37)

1. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487
2. Angelopoulou K, Stratis M and Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70: 46-51
3. Auvinen A, Isola J, Visakorpi T, Virtanen S and Hakama M (1994) Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70: 293-296
4. Baas IO, Mulder JWR, Offerhaus GJ, Vogelstein B and Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 72: 5-12
5. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair E, Taylor G, Dixon M and Quirke P (1993) Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64
6. Bosari S, Giuseppe V, Bossi P, Maggioni M, Coggi G, Murray J and Lee A (1994) Cytoplasmatic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinoma. J Natl Cancer Inst 86: 681-687
7. Bruner JM, Connely JH and Saya H (1993) p53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 6: 189-194
8. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K and May P (1987) Presence of circulating antibodies against cellular protein p53 in notable proportion of children with B-cells lymphoma. Int J Cancer 39: 185-189
9. Chang F, Syrjanen S and Syrjanen K (1995) Implications of the p53 tumour-suppressor gene in clinical oncology. J Clin Oncol 4: 1009-1022
10. Crawford LV, Pim DC and Bulbrook RD (1982) Detection of antibodies against the cellular protein p53 in the sera from patients with breast cancer. Int J Cancer 30: 403-108
11. Davidoff AM, Iglehart JD and Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442
12. Dix B, Robbins P, Soong R, Jenner D, House A and Iacopetta B (1994a) The common molecular genetic alterations in Dukes B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59: 747-751
13. Dix B, Robbins P, Carello A, House A and Iacopetta B (1994b) Comparison of p53 gene mutation and protein overexpression in colorectal carcinoma. Br J Cancer 70: 585-590
14. Dukes CE and Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12: 309-320
15. Finkelstein SD, Przygodszki R, Pricolo VE, Sakallah SA, Swalsky PA, Bakker A, Lanning R, Bland KI and Cooper DL (1996) Prediction of biologic aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping. Molec Diagn 1: 5-28
16. Goh H S, Yao J and Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5222
17. Hamelin R, Laurent-Puig GP, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106: 42-48
18. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumour-suppressor gene. N Engl J Med 329: 1318-1327
19. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) P53 mutations in human cancers. Science 253: 49-53
20. Houbiers JG, Van Der Burg SH, Van de Watering LM, Tollenaar RA, Brand A, Van de Velde CJ and Melief CJ (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 12: 637-641
21. Kressner U, Lindmark G, Gerdin B, Pahlman L and Glimelius B (1996) Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16: 951-958
22. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
23. Lindmark G, Bergström R, Påhlman L and Glimelius B (1995) The association of preoperative serum markers with Dukes stage and survival in colorectal cancer. Br J Cancer 71: 1090-1094
24. Morrin M, Kelly M, Barret N and Delaney P (1994) Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35: 1627-1631
25. Morson B and Sobin L (1976) Histological Typing of Intestinal Tumors. International Histological Classification of Tumours, No. 15, WHO: Geneva
26. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M and Leinster SJ (1994) The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115-1119
27. Mulder JWR, Bass IO, Polak MM, Goodman SN and Offerhaus GIA (1995) Evaluation of p53 protein expression as a marker for long term prognosis in colorectal carcinoma. Br J Cancer 71: 1257-1262
28. Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPherson K, Peto J and Smith P (1977) Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Surg 35: 1-39
29. Poller DN, Baxter KJ and Shepherd NA (1997) p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75: 87-93
30. Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Svalsky PA and Bland KI (1996) Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 171: 41-16
31. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B and Thomas G (1992) Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66: 758-764
32. Schlichtholtz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calyo I and Soussi T (1992) The immune reponse to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384
33. Schlichtholtz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A and Soussi T (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809-816
34. Smith DR, Ji CY, and Goh HS (1997) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74: 216-233
35. Sun XF, Carstensen JM, Zhang H, Stål O, Wingren S, Hatschek T and Nordenskjöld B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373
36. Vogelstein B and Kinzler KW (1992) P53 function and dysfunction. Cell 70: 523-526
37. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174